Get the Stockscreener App
2.65
6.00%
0.15
After Hours:
2.65
Hcw Biologics Inc stock is traded at $2.65, with a volume of 72,061.
It is up +6.00% in the last 24 hours and down -57.12% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
See More
Previous Close:
$2.50
Open:
$2.67
24h Volume:
72,061
Relative Volume:
0.04
Market Cap:
$4.23M
Revenue:
$6.59M
Net Income/Loss:
$-18.12M
P/E Ratio:
-0.2801
EPS:
-9.4605
Net Cash Flow:
$-11.45M
1W Performance:
-30.81%
1M Performance:
-57.12%
6M Performance:
-65.36%
1Y Performance:
-89.63%
1-Day Range:
$2.46
$2.67
1-Week Range:
$2.415
$4.0348
52-Week Range:
$1.50
$44.10
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
2.65 | 3.99M | 6.59M | -18.12M | -11.45M | -9.4605 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Hcw Biologics Inc Stock (HCWB) Latest News
HCW Biologics Inc (HCWB) Cash Flow - TradingKey
HCW Biologics Inc (HCWB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
HCW Biologics Inc (HCWB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
HCWB|HCW Biologics Inc|Price:2.500|Chg%:-0.380 - TradingKey
HCW Biologics Inc (HCWB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
HCW Biologics Inc (HCWB) Valuation: PE, PB & Fair Value Analysis - TradingKey
HCW Biologics Inc. Revenue Breakdown – NASDAQ:HCWB - TradingView
HCW Biologics Inc. (HCWB) Stock Price, News, Quote & History - Yahoo! Finance Canada
HCW Biologics seeks pre-IND meeting with FDA for HCW-11-018b - BioWorld News
HCW Biologics Inc (HCWB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
HCW Biologics Inc. (HCWB) stock price, news, quote and history - Yahoo Finance UK
HCW Biologics’ Cancer Candidate Targets Tissue Factor in Solid Tumors - Stock Titan
HCW Biologics (HCWB) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
HCW Biologics Q1 2026 Earnings: Positive EPS Surprise Overwhelmed by Revenue AbsenceEarnings Beat Alert - dars.gov.et
HCW Biologics (HCWB) seeks $5.6M in stock sale to fund trials, repay debt - Stock Titan
HCW Biologics Inc (HCWB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HCW Biologics Inc. Q1 2026 Earnings: Surprise EPS Beat Amidst No RevenuePre-Earnings Drift - DonanımHaber
HCW Biologics (HCWB) Declines 3.25% as Shares Approach Key Support LevelDealer Positioning - dars.gov.et
MSN Money - MSN
HCW Biologics (HCWB) Drops 8%: Testing Support Levels After Sharp DeclineSynthetic Long - dars.gov.et
HCW Biologics Regains Nasdaq Compliance, Plans Reverse Split - The Globe and Mail
HCW Biologics (HCWB) clears $2.8M disputes and $1.1M lien - Stock Titan
HCW Biologics Inc.: Top Mutual Funds Holders | QNCX | US40423R3030 - marketscreener.com
HCW Biologics Inc.: Fundamental Analysis and Financial Ratings | QNCX | US40423R3030 - marketscreener.com
HCW Biologics Inc.: Dividend historical data and projections - marketscreener.com
HCW Biologics regains Nasdaq compliance, plans stock split - Investing.com UK
HCW Biologics to Implement 1-for-6 Reverse Stock Split - Moomoo
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter - Investing News Network
HCW Biologics regains Nasdaq compliance, plans stock split By Investing.com - Investing.com Nigeria
HCW Biologics (NASDAQ: HCWB) regains bid-price compliance and sets 1-for-6 reverse split - Stock Titan
HCW Biologics Regains Nasdaq Bid Price Compliance and Announces 1-for-6 Reverse Stock Split - Quiver Quantitative
HCW BIOL: Target Price Consensus and Analysts Recommendations | HCWB | US40423R2040 - marketscreener.com
HCW Biologics clears Nasdaq bid-price rule, then splits stock 1-for-6 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
HCW Biologics executes 1-for-6 reverse stock split for Nasdaq By Investing.com - Investing.com Australia
HCW Biologics Inc (HCWB) Stock Price, Quote, News & History - Benzinga
HCW Biologics' Reverse Split: A Calculated Gamble to Secure Its Future - BriefGlance
HCW Biologics executes 1-for-6 reverse stock split for Nasdaq - Investing.com
HCW Biologics Announces 1-for-6 Reverse Stock Split to Maintain Nasdaq Listing Compliance Effective June 30, 2026 - Minichart
HCW Biologics Announces 1-for-6 Reverse Stock Split - TipRanks
HCW Biologics (NASDAQ: HCWB) enacts 1-for-6 reverse split to support Nasdaq bid-price compliance - Stock Titan
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 - GlobeNewswire
HCW Biologics Announces 1-for-6 Reverse Stock Split to Maintain Nasdaq Listing Compliance - Quiver Quantitative
HCW Biologics, Inc. Actuals & Estimates (NASDAQ:HCWB) - TradingView
Maxim Group Maintains HCW Biologics(HCWB.US) With Buy Rating, Maintains Target Price $5 - Moomoo
HCW Biologics Inc. Q1 2026 Earnings: Positive Earnings Surprise Amid No RevenueGuidance Accuracy Score - Bölüm Sonu Canavarı
[EFFECT] HCW Biologics Inc. SEC Filing - Stock Titan
HCW Biologics Inc (HCWB) Institutional Confidence - TradingKey
HCW Biologics (HCWB) files exhibits-only S-1 amendment with new exhibits - Stock Titan
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):